Scarica l'app Stockscreener
6.00
0.50%
0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLDB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.96
Aprire:
$6.06
Volume 24 ore:
513.24K
Relative Volume:
0.44
Capitalizzazione di mercato:
$466.83M
Reddito:
$14.79M
Utile/perdita netta:
$-102.44M
Rapporto P/E:
-1.9737
EPS:
-3.04
Flusso di cassa netto:
$-91.73M
1 W Prestazione:
+9.31%
1M Prestazione:
+11.13%
6M Prestazione:
+121.85%
1 anno Prestazione:
-0.99%
Intervallo 1D:
$5.91
$6.18
Intervallo di 1 settimana:
$5.215
$6.79
Portata 52W:
$2.41
$7.37
Solid Biosciences Inc Stock (SLDB) Company Profile
Nome
Solid Biosciences Inc
Settore
Industria
Telefono
617-337-4680
Indirizzo
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Confronta SLDB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.995 | 464.10M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.24 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.48 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.91 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.44 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-26 | Iniziato | Citigroup | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-13 | Iniziato | Wedbush | Outperform |
| 2024-12-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-15 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Ripresa | Piper Sandler | Overweight |
| 2024-03-28 | Iniziato | William Blair | Outperform |
| 2024-03-15 | Iniziato | Citigroup | Buy |
| 2024-03-14 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-07-12 | Iniziato | Piper Sandler | Neutral |
| 2021-05-27 | Iniziato | Jefferies | Buy |
| 2021-03-16 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Iniziato | Evercore ISI | Outperform |
| 2019-08-29 | Downgrade | Citigroup | Neutral → Sell |
| 2019-08-19 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Downgrade | Goldman | Neutral → Sell |
| 2019-02-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2019-02-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Iniziato | Citigroup | Sell |
| 2018-09-06 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Solid Biosciences Inc Borsa (SLDB) Ultime notizie
How to monitor Solid Biosciences Inc. with trend dashboards2025 Volume Leaders & AI Forecasted Entry and Exit Points - newser.com
Volume spikes in Solid Biosciences Inc. stock – what they meanJuly 2025 Rallies & AI Driven Stock Reports - newser.com
Is Solid Biosciences Inc. stock in correction or buying zoneMarket Activity Report & Safe Investment Capital Preservation Plans - newser.com
Why Solid Biosciences Inc. stock is trending among retail tradersJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
Is Solid Biosciences Inc. stock positioned for long term growthQuarterly Portfolio Report & High Accuracy Trade Signal Alerts - newser.com
Using portfolio simulators with Solid Biosciences Inc. includedWeekly Investment Report & Growth Oriented Trading Recommendations - newser.com
Price momentum metrics for Solid Biosciences Inc. explainedQuarterly Trade Summary & Capital Efficiency Focused Ideas - newser.com
Is Solid Biosciences Inc. stock ready for a breakoutTrade Volume Report & Daily Technical Stock Forecast Reports - newser.com
Solid Biosciences (NASDAQ:SLDB) Upgraded at Wall Street Zen - MarketBeat
Why Solid Biosciences Inc. stock is favored by pension fundsTrade Volume Report & Growth Oriented Trade Recommendations - newser.com
Visual trend scoring systems applied to Solid Biosciences Inc.Layoff News & Accurate Intraday Trading Signals - newser.com
Duchenne Muscular Dystrophy Drugs Market Global Forecast - GlobeNewswire
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo Finance
Solid Biosciences (NASDAQ:SLDB) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Will Solid Biosciences Inc. stock attract ESG investors2025 Earnings Impact & Real-Time Volume Analysis Alerts - newser.com
Solid Biosciences (NASDAQ:SLDB) Trading 22% HigherTime to Buy? - MarketBeat
Solid Biosciences Raises up to $50 Million in Series C Financing - Bain Capital
Can Solid Biosciences Inc. stock deliver sustainable ROE2025 Earnings Impact & High Accuracy Investment Signals - newser.com
Trend analysis for Solid Biosciences Inc. this weekForecast Cut & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Solid Biosciences Inc. forming a bottoming baseMarket Trend Report & AI Optimized Trading Strategy Guides - newser.com
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences to Present at Upcoming Scientific Meetings - GlobeNewswire
Next-Gen Duchenne Muscular Dystrophy Treatment Update: Solid Bio's Gene Therapy Trial Results Coming - Stock Titan
Electrovaya Inc Stock Analysis and ForecastDividend Stability Analysis & Stay Invested. Stay Smart. - earlytimes.in
Solid Biosciences Inc. stock volume spike explainedMarket Performance Summary & Consistent Profit Focused Trading Strategies - newser.com
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
What analysts say about Solid Biosciences Inc stockUtilities Sector Analysis & Free Daily Investment Newsletter Subscription - earlytimes.in
Solid Biosciences Inc Azioni (SLDB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Solid Biosciences Inc Azioni (SLDB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Inv | 10% Owner |
Feb 19 '25 |
Buy |
4.03 |
1,000,000 |
4,030,000 |
5,034,582 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 19 '25 |
Buy |
4.03 |
5,000,000 |
20,150,000 |
11,833,539 |
| Adage Capital Management, L.P. | 10% Owner |
Feb 18 '25 |
Buy |
7.56 |
252,545 |
1,909,240 |
4,248,084 |
| Hanrahan Jessie | Chief Regulatory Officer |
Feb 14 '25 |
Sale |
3.96 |
3,079 |
12,193 |
19,281 |
| Brooks Gabriel | Chief Medical Officer |
Feb 14 '25 |
Sale |
3.96 |
3,256 |
12,894 |
22,812 |
| Tan Kevin | CFO & Treasurer |
Feb 14 '25 |
Sale |
3.96 |
3,164 |
12,529 |
32,250 |
| Howton David T | Chief Operating Officer |
Feb 14 '25 |
Sale |
3.96 |
5,561 |
22,022 |
24,789 |
| Herzich Paul | Chief Technology Officer |
Feb 14 '25 |
Sale |
3.96 |
2,688 |
10,644 |
18,388 |
| Cumbo Alexander | President and CEO |
Feb 14 '25 |
Sale |
3.96 |
11,365 |
45,005 |
60,717 |
| Ganot Ilan | Director |
Feb 14 '25 |
Sale |
3.96 |
1,711 |
6,776 |
14,839 |
1.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):